Basal Cell Carcinoma After High Dose Rate Brachytherapy: Medium-term Dermoscopic Evaluation of Cancer's Response.
Basal cell carcinoma
Dermatoscopy
Dermoscopy
HDR brachytherapy
Skin cancer
Journal
Dermatology and therapy
ISSN: 2193-8210
Titre abrégé: Dermatol Ther (Heidelb)
Pays: Switzerland
ID NLM: 101590450
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
05
05
2023
accepted:
10
07
2023
medline:
10
8
2023
pubmed:
10
8
2023
entrez:
9
8
2023
Statut:
ppublish
Résumé
Basal cell carcinoma of the facial region remains a challenge for contemporary oncology due to the presence of aesthetic regions and critical organs. Surgery is not always the optimal solution, and high dose rate (HDR) brachytherapy has emerged as an organ-sparing treatment method whose effectiveness has been proven by a growing number of publications. Dermoscopy is a diagnostic tool that bridges clinical and pathological examination of skin lesions. It is routinely used for diagnosis, monitoring of treatment, and post-treatment evaluation; however, the literature lacks data concerning changes in dermoscopic patterns of skin cancers during and after irradiation. Our team conducted a prospective non-randomized trial of 39 patients with high-risk basal cell carcinomas (BCCs), mostly localized within the high-risk zone (H-zone) of the facial region, and who qualified for HDR brachytherapy. HDR contact brachytherapy with custom-made surface molds was introduced, delivering a dose of 45 Gy in 9 fractions prescribed to the tumor. Every patient was observed clinically and dermoscopically at three observational points: before treatment, at the end of treatment (3rd week), and 24 weeks after the end of therapy. The evolution of clinical and dermoscopic patterns was observed by two independent dermoscopists using current diagnostic criteria. A database of 12,088 photographic observations was evaluated. Univariate logistic regression proved that brachytherapy decreases the number of clinical and dermoscopic patterns typical for basal cell carcinoma, as well as dermoscopic features not related to BCC, presumably due to the formation of scar tissue. In addition, univariate logistic regression with random effects proved a positive correlation between tumor size and presence of various dermoscopic patterns typical for BCC. Dermoscopy is proven to be easy to perform and an adequate monitoring tool for patients with BCCs undergoing HDR brachytherapy.
Identifiants
pubmed: 37558829
doi: 10.1007/s13555-023-00981-5
pii: 10.1007/s13555-023-00981-5
pmc: PMC10442298
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2063-2078Informations de copyright
© 2023. The Author(s).
Références
Global Cancer Observatory, report on year 2020 https://gco.iarc.fr/today/ , Accessed July 14 2022.
Aggarwal P, Knabel P, Fleischer A. United States burden of melanoma and non-melanoma skin cancer from 1990 to 2019. J Am Acad Dermatol. 2021;85(2):388–95.
doi: 10.1016/j.jaad.2021.03.109
pubmed: 33852922
Wojciechowska U, Didkowska J, Michałek J et al. Cancer in Poland 2018, 16–21.
Zanetti R, Rosso S, Martinez C, Mossotti R, et al. Comparison of risk patterns in carcinoma and melanoma of the skin in men: a multi-centre case-case-control study. Br J Cancer. 2006;13(94):743–51.
doi: 10.1038/sj.bjc.6602982
Ciążyńska M, Kamińska-Winciorek G, Lange D, et al. The incidence and clinical analysis of non-melanoma skin cancer. Sci Rep. 2021;11:4337.
doi: 10.1038/s41598-021-83502-8
pubmed: 33619293
pmcid: 7900109
Lallas A, Apalla Z, Argenziano G, Longo C, Moscarella E, Specchio F, Zalaudek I. The dermatoscopic universe of basal cell carcinoma. Dermatol Practical Conceptual. 2014;4:11–24.
doi: 10.5826/dpc.0403a02
Guinot JL, Rembielak A, Perez-Calatayud J, Rodríguez-Villalba S, Skowronek J, Tagliaferri L, Guix B, Gonzalez-Perez V, Valentini V, Kovacs G; GEC ESTRO. GEC-ESTRO ACROP recommendations in skin brachytherapy. RadiotherOncol. 2018;126:377–385.
Krzysztofiak T, Kamińska-Winciorek G, Pilśniak A, Wojcieszek P High dose rate brachytherapy in non-melanoma skin cancer—Systematic review. Dermatologic Therapy. 2022;35(9).
Krzysztofiak T, Kamińska-Winciorek G, Tukiendorf A, Suchorzepka M, Wojcieszek P. Basal cell carcinoma treated with high dose rate (HDR) brachytherapy—early evaluation of clinical and dermoscopic patterns during irradiation. Cancers. 2021;13:5188.
doi: 10.3390/cancers13205188
pubmed: 34680336
pmcid: 8534166
American Joint Committee on Cancer. Cutaneous Squamous Cell Carcinoma of the Head and Neck. In: AJCC Cancer Staging Manual. 8th ed. Springer, New York, US, 2017;171–181.
NCCN guidelines Non Melanoma Skin Cancer, 2022, V.2. Available online: https://www.nccn.org/guidelines/guidelines-process/transparency-process-and-recommendations . Accessed on 17 July 2021.
Messina J, Epstein EH Jr, Kossard S, McKenzie C, Patel RM, Patterson JW, Scolyer RA. WHO classification of skin tumours, Basal cell carcinoma, 2018;26–34.
Tognetti L, Cinotti E, Fiorani D, et al. Long-term therapy of multiple basal cell carcinomas: Clinicodermoscopic score for monitoring of intermittent vismodegib treatment. Dermatol Ther. 2019;32: e13097.
doi: 10.1111/dth.13097
pubmed: 31612619
Kittler H, Marghoob AA, Argenziano G, et al. Standardization of terminology in dermoscopy/dermatoscopy: results of the third consensus conference of the International Society of Dermoscopy. J Am Acad Dermatol. 2016;74:1093–106.
doi: 10.1016/j.jaad.2015.12.038
pubmed: 26896294
pmcid: 5551974
Errichetti E, Zalaudek I, Kittler H, et al Standardization of dermoscopic terminology and basic dermoscopic parameters to evaluate in general dermatology (non-neoplastic dermatoses): an expert consensus on behalf of the International Dermoscopy Society. Br J Dermatol 2020;182;454–467.
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6.
doi: 10.1016/0360-3016(95)00060-C
pubmed: 7713792
R Core Team (2020). A language and environment for statistical computing. Version 4.2.1. Vienna, Austria
Dourmishev LA, Rusinova D, Botev I. Clinical variants, stages, and management of basal cell carcinoma. Indian Dermatol Online J. 2013;4:12–7.
doi: 10.4103/2229-5178.105456
pubmed: 23439912
pmcid: 3573444
Peris K, Fargnoli M, Garbe C, et al. Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines. Eur J Cancer. 2019;118:10–34.
doi: 10.1016/j.ejca.2019.06.003
pubmed: 31288208
Navarrete-Dechent C, Cordova M, Liopyris K, et al. In vivo imaging characterization of basal cell carcinoma and cutaneous response to high-dose ionizing radiation therapy: a prospective study of reflectance confocal microscopy, dermoscopy, and ultrasonography. J Am Acad Dermatol. 2021;84:1575–84.
doi: 10.1016/j.jaad.2020.07.130
pubmed: 32827607
Dörr W Radiobiology of tissue reactions. Annals of the ICRP. 2015, 44 (1_suppl), 58–68.
Apalla Z, Lallas A, Tzellos T, et al. Applicability of dermoscopy for evaluation of patients’ response to nonablative therapies for the treatment of superficial basal cell carcinoma. Br J Dermatol. 2014;170:809–15.
doi: 10.1111/bjd.12749
pubmed: 24283541
Aróstegui Aguilar J, Hervella Garcés M, Yanguas Bayona JI, Azcona Rodríguez M. Dermoscopic signs as predictors of non-response to imiquimod treatment in superficial basal cell carcinoma. An Sist Sanit Navar. 2019;42:303–7.
doi: 10.23938/ASSN.0722
pubmed: 31859267
Husein-ElAhmed H, Fernandez-Pugnaire MA. Dermatoscopy-guided therapy of pigmented basal cell carcinoma with imiquimod. An Bras Dermatol. 2016;91:764–9.
doi: 10.1590/abd1806-4841.20165255
pubmed: 28099598
pmcid: 5193187
Reddy N, Nguyen BT. The utility of optical coherence tomography for diagnosis of basal cell carcinoma: a quantitative review. Br J Dermatol. 2019;180:475–83.
doi: 10.1111/bjd.17201
pubmed: 30216419
Iftimia N, Sahu A, Cordova M, et al. The potential utility of integrated reflectance confocal microscopy-optical coherence tomography for guiding triage and therapy of basal cell carcinomas. J Cancer. 2020;18:6019–24.
doi: 10.7150/jca.47026